Development based in Switzerland
What we use
and how we do it
Our vaccine platform relies on state-of-the-art genetic engineering technologies allowing the rapid generation and development of next-generation vaccines.
We have developed and acquired a number of technologies enabling targeted genetic manipulation of viruses. Our platform aims at efficient production of novel and safe vaccines that will target reliable protection against circulating and emerging viral diseases.
RocketVax is taking a unique approach to vaccination against SARS-CoV-2. Instead of only using one target antigen (spike protein), we develop recombinant virus vaccines that contain all major immunogenic features of SARS-CoV-2 but cannot or are limited in their ability to spread, making them safe and efficacious.
Advantages of the solution
The next generation SARS-CoV-2 vaccines developed by RocketVax and its collaboration partners present notable advantages. In contrast to the currently available first-generation vaccines, single-cycle and live-attenuated virus vaccines expose the entire repertoire of SARS-CoV-2 antigens to the immune system, thereby triggering strong and broad B-cell and T-cell responses against a wide variety of targets making our vaccines potentially active against all the SARS-CoV-2 variants of concern. We will use intranasal vaccination that potentially will trigger broad and long-lasting immunity, including mucosal immunity. Notably, the needle-free, nasal administration of our virus vaccines adequately addresses current challenges and meets the requirements for sustainable large scale vaccination campaigns. Finally, our vaccines are expected to be stable at the higher temperatures making the logistics of vaccine distribution more favorable. Should the need arise, our inventive approaches allow for a quick modification of our vaccines, making our concept highly flexible and adaptable to novel virus variants of concern.
Versatility of the system
Our vaccines do not require artificial lipid-encapsulation or very low temperature storage and shipping conditions. No foreign vector-sequences are present in our vaccines that would be immunogenic themselves and could lead to reduced protection levels or a lower boosting response against Covid-19 due to unwanted pre-existing immunity against the vector. Previous infection with SARS-CoV-2 or prior Covid-19 vaccination therefore do not preclude vaccination with our vaccines. The platform also offers the potential to extend to the generation of vaccines against other viral diseases as well as cancer.
Our vaccine strategy
of novel vaccine vector
and molecular biology